BreEStim in Managing Neuropathic Pain After Spinal Cord Injury (SCI)
A Randomized, Double-blind, Sham-controlled, Parallel-group Trial Designed to Evaluate the Efficacy of BreEStim in Managing Neuropathic Pain After Spinal Cord Injury (SCI)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Sheng Li, MD, PhD
- Phone Number: (713) 797-7125
- Email: sheng.li@uth.tmc.edu
Study Contact Backup
- Name: Shengai Li, MS
- Phone Number: 713-797-7561
- Email: shengai.li@uth.tmc.edu
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas Health Science Center at Houston
-
Contact:
- Shengai Li
- Phone Number: 713-797-7561
- Email: shengai.li@uth.tmc.edu
-
Contact:
- Sheng Li, MD, PhD
- Phone Number: 7137977125
- Email: sheng.li@uth.tmc.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- has a history of SCI > 1 year
- has a DN4 (Douleur Neuropathique en 4 Questions) score of 4 or greater
- has neuropathic pain >3 months
- is stable on oral pain medications at least one month
- Able to tolerate BreEStim treatment for 1 minute
Exclusion Criteria:
- is on a mechanical ventilator
- is currently having active urinary tract infection (UTI)
- does not have any residual sensation in the arms
- has other pain (musculoskeletal, visceral etc.), but not neuropathic, e.g., shoulder pain from wheelchair use
- has a pacemaker to avoid possible side effect of electrical stimulation
- is not able to follow commands, or to give consent
- has asthma or other pulmonary disease
- has a history of cardiac pathology, implanted pacemakers, or current use of rhythm altering medication like beta-blockers
- has baclofen pump or deep brain implants
- has respiratory tract/sinus infection and rhinorrhea
- has low motor neuron injury that no responses will be triggered by electrical stimulation
- has severe mental disorders (e.g., depression, substance abuse) and is receiving active treatment and frequent monitoring
- is not medically stable
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Active BreEStim Treatment
|
During the Active BreEStim Treatment session, participants will remain relaxed while breathing is monitored using a nasal cannula.
Surface electrodes will be placed over the median nerve at the wrist or another selected peripheral nerve.
Electrical stimulation will be synchronized with voluntary breathing and delivered at an individually tolerated intensity for approximately 30 minutes.
|
|
Sham Comparator: Sham BreEStim Treatment
|
During the Sham BreEStim Treatment session, participants will remain relaxed while breathing is monitored using a nasal cannula.
Surface electrodes will be placed over the median nerve at the wrist or another selected peripheral nerve.
Electrical stimulation will be synchronized with voluntary breathing and delivered at the sensory threshold level for approximately 30 minutes.
|
|
Active Comparator: The transcutaneous electrical nerve stimulation (TENS) Treatment
|
During the TENS Treatment session, participants will remain relaxed while transcutaneous electrical stimulation is applied through surface electrodes placed over the painful area.
Stimulation will be delivered at an individually tolerated intensity for approximately 30 minutes.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Pain Level as Measured by the Visual Analog Scale (VAS).
Time Frame: Baseline, 10-15 minutes after intervention
|
VAS scores are recorded from 0 to 10 with 0 being "no pain" and 10 being "worst pain", a higher score indicating a higher level of pain.
Change is reported as [(VAS score at baseline) - (VAS Score 10 minutes after intervention)] - a positive value indicates that the score (and pain level) decreased.
Mean VAS difference will be compared.
|
Baseline, 10-15 minutes after intervention
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the difference in the percentage of responders between active BreEStim and Sham BreEStim groups
Time Frame: Baseline, 10-15 minutes after intervention
|
Given sham-controlled design, the investigators define responders as individual participants who achieve at least a 30% reduction in pain from their individual baseline scores.
|
Baseline, 10-15 minutes after intervention
|
|
the difference in the percentage of responders between between active BreEStim and transcutaneous electrical nerve stimulation (TENS) groups.
Time Frame: Baseline, 10-15 minutes after intervention
|
Given sham-controlled design, the investigators define responders as individual participants who achieve at least a 30% reduction in pain from their individual baseline scores.
|
Baseline, 10-15 minutes after intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Sheng Li, MD, PhD, The University of Texas Health Science Center, Houston
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- HSC-MS-26-0102
- UG3NS139014 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.